Limited effectiveness, weight regain, and high prevalence of adverse events are the three key limitations of semaglutide ...

New research reveals that semaglutide significantly improves liver health in MASH patients. A new study published in the New ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

Limited effectiveness, weight regain, and high prevalence of adverse events are the three key limitations of ...

The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.

Taking semaglutide and liraglutide — a lesser-known active ingredient — medications for weight loss cut their consumption by ...

DelveInsight's analysis forecasts liver fibrosis market growth due to the introduction of emerging therapies, expecting an increase in market ...

The NHS has been urged to accelerate the rollout of weight loss drugs to “many millions” of people, as experts hailed the start of a “golden age” of anti-obesity treatments. A raft of studies ...

A new study suggests that semaglutide, the active ingredient in Ozempic, may help decrease liver fat, inflammation, and ...

Semaglutide can rapidly reduce heart attacks and other serious cardiovascular complications in adults with overweight or ...

First-generation GLP-1 weight-loss drugs can help reduce the risk of obesity-related cancers, new research shows. Liraglutide ...

Novo Nordisk’s Wegovy (semaglutide injection) 2.4mg has demonstrated early protection against heart disease, according to new ...